Targeted repression of overexpressed CD30 downregulates NF-κB and ERK1/2 pathway in Hodgkin lymphoma cell lines

Oncology Research

Volumn 19, Issue 10-11, 2012, Pages 463-469

  Watanabe, Mariko ^a   Nakano, Kazumi ^b   Togano, Tomiteru ^a   Nakashima, Makoto ^a,b   Higashihara, Masaaki ^a   Kadin, Marshall E ^c   Watanabe, Toshiki ^b   Horie, Ryouichi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD30; ERK1 2; A20; Hodgkin lymphoma; I B ; NF B

Indexed keywords

CD30 ANTIGEN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TUMOR SUPPRESSOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; HODGKIN DISEASE; LYMPHOCYTE TRANSFORMATION; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84855989453     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504012X13285365944292     Document Type: Article

References (21)

1. Diehl, V.; Thomas, R. K.; Re, D. Part II: Hodgkin's lymphoma - diagnosis and treatment. Lancet Oncol. 5:19-26; 2004.
2. Watanabe, M.; Ogawa, Y.; Ito, K.; Higashihara, M.; Kadin, M. E.; Abraham, L. J.; Watanabe, T.; Horie, R. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 163:633-641; 2003.
3. Bargou, R. C.; Leng, C.; Krappmann, D.; Emmerich, F.; Mapara, M. Y.; Bommert, K.; Royer, H. D.; Scheidereit, C.; Dorken, B. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87:4340-4347; 1996.
4. Zheng, B.; Fiumara, P.; Li, Y.; Georgakis, G. V.; Snell, V.; Younes, M.; Vauthey, J. N.; Carbone, A.; Younes, A. MEK/ERK pathway is constitutively active in Hodgkin disease: A shared signaling pathway among CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102:1019-1027; 2003.
5. Horie, R.; Watanabe, T.; Morishita, Y.; Ito, K.; Ishida, T.; Kanegae, Y.; Saito, I.; Higashihara, M.; Mori, S.; Kadin, M. E. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21:2493-2503; 2002.
6. Croager, E. J.; Gout, A. M.; Abraham, L. J. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am. J. Pathol. 156:1723-1731; 2000.
7. Watanabe, M.; Sasaki, M.; Itoh, K.; Higashihara, M.; Umezawa, K.; Kadin, M. E.; Abraham, L. J.; Watanabe, T.; Horie, R. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res. 65:7628-7634; 2005.
8. Wertz, I. E.; O'Rourke, K. M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; Boone, D. L.; Ma, A.; Koonin, E. V.; Dixit, V. M. Deubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430:694-699; 2004.
9. Zhang, J.; Stirling, B.; Temmerman, S. T.; Ma, C. A.; Fuss, I. J.; Derry, J. M.; Jain, A. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J. Clin. Invest. 116:3042-3049; 2006.
10. Gilmore, T. D. Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 25:6680-6684; 2006.
11. Schmitz, R.; Hansmann, M. L.; Bohle, V.; Martin-Subero, J. I.; Hartmann, S.; Mechtersheimer, G.; Klapper, W.; Vater, I.; Giefing, M.; Gesk, S.; Stanelle, J.; Siebert, R.; Kuppers, R. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. 206:981-989; 2009.
12. Schmidt, A.; Schmitz, R.; Giefing, M.; Martin-Subero, J. I.; Gesk, S.; Vater, I.; Massow, A.; Maggio, E.; Schneider, M.; Hansmann, M. L.; Siebert, R.; Kuppers, R. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma. Genes Chromosomes Cancer 49:803-809.
13. Cabannes, E.; Khan, G.; Aillet, F.; Jarrett, R. F.; Hay, R. T. Mutations in the IkappaBalpha gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18:3063-3070; 1999.
14. Watanabe, M.; Dewan, M. Z.; Taira, M.; Shoda, M.; Honda, M.; Sata, T.; Higashihara, M.; Kadin, M. E.; Watanabe, T.; Yamamoto, N.; Umezawa, K.; Horie, R. IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. Lab. Invest. 87:372-382; 2007.
15. Andrews, N. C.; Faller, D. V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:2499; 1991.
16. Mathas, S.; Hinz, M.; Anagnostopoulos, I.; Krappmann, D.; Lietz, A.; Jundt, F.; Bommert, K.; Mechta-Grigoriou, F.; Stein, H.; Dorken, B.; Dorken, B.; Scheidereit, C. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize wisurname the NF-kappa B. EMBO J. 21:4104-4113; 2002.
17. Zabel, U.; Henkel, T.; Silva, M. S.; Baeuerle, P. A. Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus. EMBO J. 12:201-211; 1993.
18. Watanabe, M.; Ohsugi, T.; Shoda, M.; Ishida, T.; Aizawa, S.; Maruyama-Nagai, M.; Utsunomiya, A.; Koga, S.; Yamada, Y.; Kamihira, S.; Okayama, A.; Kikuchi, H.; Uozumi, K.; Yamaguchi, K.; Higashihara, M.; Umezawa, K.; Watanabe, T.; Horie, R. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106:2462-2471; 2005.
19. Bargou, R. C.; Emmerich, F.; Krappmann, D.; Bommert, K.; Mapara, M. Y.; Arnold, W.; Royer, H. D.; Grinstein, E.; Greiner, A.; Scheidereit, C.; Dorken, B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100:2961-2969; 1997.
20. Watanabe, M.; Ogawa, Y.; Itoh, K.; Koiwa, T.; Kadin, M. E.; Watanabe, T.; Okayasu, I.; Higashihara, M.; Horie, R. Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. Lab. Invest. 88:48-57; 2008.
21. Davidson, B. L.; McCray, Jr., P. B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12:329-340; 2011.